Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.79 · Revenue $7.24M · 1 analysts
Est. EPS $-0.68 · Revenue $7.45M · 1 analysts
Est. EPS $-5.70 · Revenue $25.24M · 1 analysts
Est. EPS $-0.49 · Revenue $10.10M · 1 analysts
EPS $-2.40 · Revenue $6.20M
EPS $-6.96 · Revenue $5.72M
EPS $-5.52 · Revenue $5.03M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $22.0M | -14.1% | +68.8% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-19.9M | +31.2% | -6.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +38.2% | +19.5% | +19.6% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -76.7% | -0.6% | +76.2% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -90.4% | +19.9% | +36.8% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-16.8M | +22.5% | -63.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -76.4% | +9.8% | +3.2% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 52.2% | +1017.6% | -85.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.31x | -37.0% | -48.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $22.9M | -24.9% | +4.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -17.16 vs -10.68 | -60.7% | -4.12 vs -1.39 | -197.2% |
| Revenue Surprise | $22.0M vs $25.0M | -11.8% | $6.6M vs $6.5M | +1.4% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Hexter Joshua | — | — | — | 0 | — |
| Aug 20, 2026 | Gabay Avraham | director | Ordinary Shares, no par value per share | A | 13,643 | — |
| Aug 20, 2026 | Gabay Avraham | director: | — | — | 0 | — |
| Aug 14, 2026 | Greenwald Yonason | director | Ordinary Shares, no par value per share | A | 6,711 | — |
| Aug 14, 2026 | Greenwald Yonason | director: | — | — | 0 | — |
Operator: Good morning, and welcome to the First Quarter 2026 Lifeward Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Almog Adar, CFO of Lifeward. Please go ahead. Almog Adar: Thank you, Drew, and thanks, everyone, who has joined us on the call today. My name is Almog Adar, I'm Lifeward' Chief Financial Officer. And with me on today's call is our President and Chief Executive Officer, Mark Grant. Earlier this morning, Lifeward issued a press release detailing the financial results for the first quarter ended March 31, 2026. I would ask you to review the full text of our forward-looking statements from the press release. We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC. With that, I will turn the call over to Mark. William Grant: Thank you, Almog, and thank you for everybody for joining us today. The first quarter of 2026 marked an important strategic milestone for Lifeward as we successfully completed the acquisition of Oratech. We believe this transaction significantly strengthens Lifeward's position as a diversified biomedical innovation company while reinforcing our focus on neurorehabilitation and our path toward profitability. We believe this was a highly strategic and capital-efficient transaction for Lifeward shareholders. Through the equity-based acquisition of Oratech, we gained access to the protein oral delivery platform, a potentially transformative technology across many therapeutic indications, including ORMD-0801 oral insulin, which is expected to commence a Phase II study. Importantly, the clinical program management responsibilities remain with Oramed, utilizing funds previously transferred to Oratech as part of the strategic transaction. That means Lifeward and our shareholders by owning the protein orally delivered platform outright effectively receive a meaningful option on the potential success of the promising technology with minimal near-term operational burden, no material increase in operating expenses and limited management bandwidth requirements beyond my own involvement, supporting strategic oversight and development guidance. As many of you know, my background includes extensive experience in diabetes and metabolic disease, and I believe this platform has meaningful long-term potential. At the same time, Lifeward's core focus remains firmly centered on scaling our neurorehabilitation MedTech business. The second key takeaway from the quarter is Lifeward is now substantially better positioned on its path to profitability. With the $10 million from our convertible note financing, we have significantly strengthened our balance sheet and improved our operating flexibility. This allows us to stabilize and build upon the fundamental and foundational work we have done over the last several quarters, while …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
William Mark Grant | President, Chief Executive Officer & Director | USD 614,583 | Male | 1971 | Active |
Jeannine Lynch | Vice President of Market Access & Strategy | USD 367,966 | Female | 1966 | Active |
Almog Adar | Chief Financial Officer | USD 339,133 | Male | 1985 | Active |
Miri Pariente | Vice President of Operations, Regulatory & Quality | USD 295,351 | Female | 1977 | Active |
Keith Dale Rose | Chief Medical Officer | — | — | — | Active |
Judy Kula | Vice President of Customer Service, Human Resources & Business Affairs | — | Female | — | Active |
Craig Peters | Vice President of Sales - North America | — | Male | — | Active |
Lifeward (LFWD) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to a loss of $6.96 per share a year ago.
Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support con tinued commercial execution HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its second quarter 2026 financial results on Friday, August 14, 2026. A press release will be issued and quarterly report will be filed with the SEC prior to 9:30 a.m. ET. The Company will not conduct a conference call.
Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , bring s extensive clinical expertise and patient care infrastructure A dvances Lifeward's strategy to broaden ReWalk access through capital-efficient channel partner model intended to accelerate growth, expand patient access and improve commercial scalability HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones
